Ligand Pharmaceuticals (LGND) – Research Analysts’ Recent Ratings Updates

Ligand Pharmaceuticals (NASDAQ: LGND) has recently received a number of price target changes and ratings updates:

• 11/25/2025 – Ligand Pharmaceuticals had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Ligand Pharmaceuticals had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/10/2025 – Ligand Pharmaceuticals had its price target raised by analysts at Royal Bank Of Canada from $185.00 to $234.00. They now have an “outperform” rating on the stock.
• 11/7/2025 – Ligand Pharmaceuticals was upgraded by analysts at Weiss Ratings from a “sell (d+)” rating to a “hold (c-)” rating.
• 11/7/2025 – Ligand Pharmaceuticals had its price target raised by analysts at Benchmark Co. from $175.00 to $220.00. They now have a “buy” rating on the stock.
• 11/6/2025 – Ligand Pharmaceuticals had its price target raised by analysts at HC Wainwright from $206.00 to $231.00. They now have a “buy” rating on the stock.
• 11/3/2025 – Ligand Pharmaceuticals had its price target raised by analysts at Oppenheimer Holdings, Inc. from $190.00 to $250.00. They now have an “outperform” rating on the stock.
• 10/8/2025 – Ligand Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.

Insider Activity

In related news, Director Jason Aryeh sold 10,000 shares of the company’s stock in a transaction dated Tuesday, September 23rd. The stock was sold at an average price of $170.81, for a total value of $1,708,100.00. Following the completion of the sale, the director owned 69,289 shares in the company, valued at approximately $11,835,254.09. This represents a 12.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director John W. Kozarich sold 467 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $191.05, for a total value of $89,220.35. Following the transaction, the director owned 44,588 shares of the company’s stock, valued at $8,518,537.40. The trade was a 1.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 11,401 shares of company stock worth $1,956,894 in the last ninety days. Insiders own 7.00% of the company’s stock.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.